Efficacy and safety of combination of sorafenib and transarterial chemoembolization in treating primary hepatocellular carcinoma / 中国医学科学院学报
Acta Academiae Medicinae Sinicae
;
(6): 33-36, 2014.
Article
Dans Chinois
| WPRIM
| ID: wpr-285930
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy and safety of the combination of sorafenib and transarterial chemoembolization (TACE)in the treatment of primary hepatocellular carcinoma (HCC).</p><p><b>METHODS</b>The clinical data of 10 patients with unresectable HCC treated by sorafenib combined with TACE in the Department of Radiology, the First Hospital of China Medical University were retrospectively analyzed. The efficacy was evaluated according to the modified Response Evaluation Criteria in Solid Tumors assessment. Survival was analyzed by Kaplan-Meier method. Safety was evaluated according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 3.0.</p><p><b>RESULTS</b>Among the 10 patients, 2 achieved complete response, 3 achieved partial response, 3 achieved stable disease, and 2 experienced progressive disease. The median overall survival of the cohort was 29.5 months. Different degree of adverse drug reactions (ADRs) occurred in 9 patients but all were at grade 3 or lower. The most common ADRs were hand-foot skin reaction (7/10) and diarrhea (6/10).</p><p><b>CONCLUSION</b>The combination of sorafenib and TACE is an effective and safe treatment for HCC.</p>
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Phénylurées
/
Thérapeutique
/
Études rétrospectives
/
Résultat thérapeutique
/
Chimioembolisation thérapeutique
/
Nicotinamide
/
Carcinome hépatocellulaire
/
Utilisations thérapeutiques
/
Tumeurs du foie
/
Antinéoplasiques
Type d'étude:
Étude observationnelle
Limites du sujet:
Adulte
/
Adulte très âgé
/
Aged80
/
Femelle
/
Humains
/
Mâle
langue:
Chinois
Texte intégral:
Acta Academiae Medicinae Sinicae
Année:
2014
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS